Regenxbio Inc. (NASDAQ:RGNX) fell 3.4% during mid-day trading on Wednesday . The company traded as low as $11.53 and last traded at $11.78, with a volume of 61,291 shares trading hands. The stock had previously closed at $12.19.

A number of research firms recently issued reports on RGNX. Zacks Investment Research raised shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. set a $25.00 price target on shares of Regenxbio and gave the company a “buy” rating in a research note on Thursday, August 18th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.75.

The stock has a 50 day moving average of $9.92 and a 200 day moving average of $10.91. The firm’s market cap is $309.91 million.

Regenxbio (NASDAQ:RGNX) last issued its earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. Equities analysts forecast that Regenxbio Inc. will post ($2.37) earnings per share for the current year.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.